A major international study led by University College London (UCL) has demonstrated that the Prosigna gene test can identify early-stage breast cancer patients who can safely forgo chemotherapy. The trial involved more than 4,400 women across six countries, concluding that hormone therapy alone is sufficient for a significant portion of patients.

How 4,400 patients proved the efficacy of Prosigna

The clinical trial, which spanned the UK, Norway, Sweden, Australia, New Zealand, and Thailand, focused on patients aged 40 and older. According to the report, the Prosigna test analyzes the activity of specific genes linked to breast cancer growth to determine if chemotherapy would provide a meaningful benefit. The results were stark: more than two-thirds of the 4,400 participants were found to be candidates for hormone therapy alone without an increased risk of cancer recurrence or death within a five-year window.

This shift toward genomic screening represents a broader movement in oncology to move away from "one-size-fits-all" protocols. Historically, chemotherapy was the standard for early-stage patients with lymph node involvement to lower recurrence risks,but the Prosigna trial suggests that for many, the toxicity of the treatment outweighs the clinical gain.

Karen Bonham's journey from diagnosis to chemotherapy avoidance

The human impact of this precision approach is exemplified by Karen Bonham, a 64-year-old former speech and language therapist from Cardiff. After a routine screening in June 2017 led to a breast cancer diagnosis, Bonham joined the UCL trial to see if she could avoid the physical toll of chemotherapy. as the report describes, Bonham's low Prosigna score indicated that chemotherapy would offer minimal benefit, allowing her to pursue a regimen of radiotherapy and hormone therapy instead.

Nearly nine years after her diagnosis, Bonham reports that she has maintained an active lifestyle involving yoga and walking, stating that the cancer no longer defines her life. her experience highlights the emotional relief that accompanies the removal of aggressive treatments when they are clinically unnecessary.

Sparing 5,000 NHS patients from chemotherapy annually

From a systemic perspective, the implications for public health are substantial. professor Rob Stein, the chief investigator and professor of breast oncology at the UCL Cancer Institute, noted that the results allow treatment decisions to be guided by tumor biology rather than just traditional clinical features.. The UCL researchers estimate that these findings could spare more than 5,000 National Health Service (NHS) patients in the UK from chemotherapy every year.

By reducing the number of patients undergoing unnecessary chemotherapy, health systems can allocate resources more efficiently while sparing thousands of women from long-term side effects. this transition toward personalized medicine aligns with global trends in healthcare that prioritize targeted therapies over broad-spectrum interventions.

The missing data for pre-menopausal women

Despite the success of the trial, a significant gap in the data remains regarding younger patients. The current findings apply exclusively to women aged 40 and over, leaving it unknown if the Prosigna test is equally reliable for pre-menopausal women. While the report mentions that further research on this demograaphic is planned, the results are expected to be several years away.

This leaves clinicians in a difficult position when treating younger patients, as they must still rely on traditional clinical markers rather than the genomic insights provided by Prosigna. Until these studies are completed, the "personalized" promise of this test remains unavailable to a critical subset of the breast cancer population.